THE EFFECT OF Pyrenacantha staudtii ON SUB-CHRONIC, HEPATIC TOXICITY

ABSTRACT

Pyrenacantha staudtii, a plant traditionally used in folk medicine, has recently gained attention for its potential therapeutic properties. In this study, we aimed to investigate both the sub-chronic hepatologic toxicity and the α-amylase inhibitory activity of Pyrenacantha staudtii extract. To assess sub-chronic toxicity, Sprague-Dawley rats were orally administered varying doses of Pyrenacantha staudtii extract daily for 28 days, while control groups received vehicle only. At the end of the study period, serum biomarkers indicative of liver function, such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP), were monitored. Our findings revealed no significant alterations in serum biomarkers or histopathological changes in the liver tissues, indicating the absence of sub-chronic hepatologic toxicity within the administered doses of Pyrenacantha staudtii extract. Furthermore, we investigated the α-amylase inhibitory activity of the extract using in vitro assays. Interestingly, further analysis revealed a stimulatory effect on α-amylase secretion, suggesting a complex regulatory mechanism involving stimulation rather than inhibition of enzyme activity. This dual activity could be beneficial in the management of hypoglycemia. In conclusion, our study provides valuable insights into the safety profile and potential therapeutic effects of Pyrenacantha staudtii extract. While no sub-chronic hepatologic toxicity was observed, the extract exhibited a significant stimulatory effect on α-amylase secretion rather than inhibitory activity. Further investigations are warranted to elucidate the underlying mechanisms and explore the therapeutic potential of Pyrenacantha staudtii in the management of metabolic disorders.